| Title | [Palliative treatment for colorectal cancer] | | Author(s) | Hegewisch-Becker S, Vanhoefer U, Kubicka S, Pech M, Moehler M, Riess H, Hartmann JT, Malek N, Rödel C, Arnold D | | Institution | Gemeinschaftspraxis, Hamburg, Deutschland. | | Source | Onkologie 2009.:13-6. | | Abstract | Before a decision is made to give a particular drug treatment, first of all the best strategy for the individual patient must be determined. In a patient with an aggressive tumour, for whom a secondary curative approach by means of metastasis resection is not an option, the preferred first-line treatment will generally be a triple combination therapy containing bevacizumab - and this is also true in KRAS/BRAF wild-type patients, since the main aim here is to achieve the longest possible survival time with a minimum of side effects. If an epidermal growth factor receptor (EGFR) antibody (cetuximab or panitumumab) is to be used in first-line or later therapy, then the presence of a KRAS mutation must be excluded beforehand. It is very likely sensible also to exclude a BRAF mutation. Second-line treatment after a first-line therapy containing bevacizumab may be a combination chemotherapy or, in patients who are KRAS wild-type (and possibly also BRAF wild-type), irinotecan plus cetuximab. Locoregional treatments such as chemoembolisation, selective internal radiation therapy (SIRT), and stereotactic | | Language | ger | | Pub Type(s) | English Abstract
Journal Article
| | PubMed ID | 19546597 |
|
